A multiplex technology platform for the rapid analysis of clinically actionable genetic alterations and validation for BRAF p.V600E detection in 1549 cytologic and histologic specimens

Archives of Pathology and Laboratory Medicine

Volumn 138, Issue 3, 2014, Pages 371-378

  Smith, David L ^a   Lamy, Aude ^b   Beaudenon Huibregtse, Sylvie ^a   Sesboüé, Richard ^c   Laosinchai Wolf, Walairat ^a   Sabourin, Jean Christophe ^b   Labourier, Emmanuel ^a  

^a ASURAGEN INC   (United States)

^b ROUEN UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE ROUEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN;

ARTICLE; COLORECTAL TUMOR; EQUIPMENT; GENETICS; HUMAN; METHODOLOGY; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; THYROID NODULE; THYROID TUMOR;

COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; HUMANS; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS; THYROID NODULE;

EID: 84895544858     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2013-0002-OA     Document Type: Article

References (29)

1. West H, Lilenbaum R, Harpole D, Wozniak A, Sequist L. Molecular analysis-based treatment strategies for the management of non-small cell lung cancer. J Thorac Oncol. 2009;4(9):S1029-S1039.
2. Monzon FA, Ogino S, Hammond ME, Halling KC, Bloom KJ, Nikiforova MN. The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer. Arch Pathol Lab Med. 2009;133(10): 1600-1606.
3. Wang HL, Lopategui J, Amin MB, Patterson SD. KRAS mutation testing in human cancers: the pathologist's role in the era of personalized medicine. Adv Anat Pathol. 2010;17(1): 23-32.
4. Safaee Ardekani G, Jafarnejad SM, Tan L, Saeedi A, Li G. The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLoS One. 2012;7(10):e47054.
5. Van Cutsem E, Kohne CH, Lang I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29(15): 2011-2019.
6. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364(26): 2507-2516.
7. Bollag G, Tsai J, Zhang J, et al. Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov. 2012;11(11): 873-886.
8. Mehta V, Nikiforov YE, Ferris RL. Use of molecular biomarkers in FNA specimens to personalize treatment for thyroid surgery [published online ahead of print September 13, 2012]. Head Neck. doi:10.1002/hed.23140.
9. Nikiforov YE. Molecular analysis of thyroid tumors. Mod Pathol. 2011;24: S34-S43.
10. Weichert W, Schewe C, Lehmann A, et al. KRAS genotyping of paraffinembedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology. J Mol Diagn. 2010;12(1): 35-42.
11. Kwon MJ, Lee SE, Kang SY, Choi YL. Frequency of KRAS, BRAF, and PIK3CA mutations in advanced colorectal cancers: comparison of peptide nucleic acid-mediated PCR clamping and direct sequencing in formalin-fixed, paraffin-embedded tissue. Pathol Res Pract. 2011;207(12): 762-768.
12. Gonzalez de Castro D, Angulo B, Gomez B, et al. A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens. Br J Cancer. 2012;107(2): 345-351.
13. Halait H, Demartin K, Shah S, et al. Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma. Diagn Mol Pathol. 2012;21(1): 1-8.
14. Harbison CT, Horak CE, Ledeine JM, et al. Validation of companion diagnostic for detection of mutations in codons 12 and 13 of the KRAS gene in patients with metastatic colorectal cancer: analysis of the NCIC CTG CO.17 trial [published online ahead of print October 3, 2012]. Arch Pathol Lab Med. doi:10. 5858/arpa.2012-0367-OA.
15. Lamy A, Blanchard F, Le Pessot F, et al. Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls. Mod Pathol. 2011;24(8): 1090-1100.
16. Lurkin I, Stoehr R, Hurst CD, et al. Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes. PLoS One. 2010;5(1):e8802.
17. Laosinchai-Wolf W, Ye F, Tran V, et al. Sensitive multiplex detection of KRAS codons 12 and 13 mutations in paraffin-embedded tissue specimens. J Clin Pathol. 2011;64(1): 30-36.
18. Defoort JP, Martin M, Casano B, Prato S, Camilla C, Fert V. Simultaneous detection of multiplex-amplified human immunodeficiency virus type 1 RNA, hepatitis C virus RNA, and hepatitis B virus DNA using a flow cytometer microsphere-based hybridization assay. J Clin Microbiol. 2000;38(3): 1066-1071.
19. Dunbar SA, Jacobson JW. Application of the luminex LabMAP in rapid screening for mutations in the cystic fibrosis transmembrane conductance regulator gene: a pilot study. Clin Chem. 2000;46(9): 1498-1500.
20. Ye F, Laosinchai-Wolf W, Labourier E. An optimized technology platform for the rapid multiplex molecular analysis of genetic alterations associated with leukemia. Cancer Genet. 2012;205(10): 488-500.
21. Ye F, Li MS, Taylor JD, et al. Fluorescent microsphere-based readout technology for multiplexed human single nucleotide polymorphism analysis and bacterial identification. Hum Mutat. 2001;17(4): 305-316.
22. Quach N, Goodman MF, Shibata D. In vitro mutation artifacts after formalin fixation and error prone translesion synthesis during PCR. BMC Clin Pathol. 2004;4(1): 1.
23. Smyth P, Finn S, Cahill S, et al. RET/PTC and BRAF act as distinct molecular, time-dependant triggers in a sporadic Irish cohort of papillary thyroid carcinoma. Int J Surg Pathol. 2005;13(1): 1-8.
24. Armbruster DA, Pry T. Limit of blank, limit of detection and limit of quantitation. Clin Biochem Rev. 2008;29:S49-S52.
25. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998;17(8): 857-872.
26. Armitage P, Berry G. Statistical Methods in Medical Research. London, England: Blackwell Scientific Publications; 1994.
27. Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol. 2003;56(11): 1129-1135.
28. Franklin WA, Haney J, Sugita M, Bemis L, Jimeno A, Messersmith WA. KRAS mutation: comparison of testing methods and tissue sampling techniques in colon cancer. J Mol Diagn. 2010;12(1): 43-50.
29. Anderson S, Bloom KJ, Vallera DU, et al. Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma. Arch Pathol Lab Med. 2012;136(11): 1385-1391.